Novartis: Eczema trials

The registry lists 11 Eczema studies with Novartis as lead sponsor. 2 are open to participants now and 3 have results posted.

Phase 1 2Phase 2 5Phase 3 1Phase 4 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07604324Phase 1
• Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic DermatitisRecruitingNCT06947993Phase 2
• A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.CompletedNCT04836858Phase 2Results posted
• A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis PatientsTerminatedNCT03948334Phase 2Results posted
• A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic DermatitisTerminatedNCT03517566Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton SyndromeCompletedNCT01428297Phase 1
• Safety and Efficacy of DNK333 in Atopic Dermatitis PatientsCompletedNCT01033097Phase 2
• Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-oldCompletedNCT00510003Phase 4
• Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic DermatitisCompletedNCT00367393Phase 4
• Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic DermatitisCompletedNCT00351052Phase 3
• Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic DermatitisCompletedNCT00150059Phase 4